Balfour Capital Group Researched Novartis AG on March 17th, 2023.
Novartis AG, is a global pharmaceutical company renowned for its research-driven healthcare solutions that address a wide range of medical needs, improving patient lives worldwide.
The chart's commencement marks the instance of our stock recommendation.
We have established a Buy recommendation at $77.03 on March 17th, 2023.
Our designated price target stands at $120.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
Company Snapshot
Balfour Capital Group's precise and thorough research crafted by our team of analysts.
Balfour Capital Group wants to clarify that our recommendation to Buy Novartis AG ADR (NVS) is based on thorough research conducted by our
dedicated teams. We invest significant time and resources in analyzing market
trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee
any specific financial outcomes. The decision to act on our recommendation
should be made at your discretion. Please be aware that investments carry
inherent risks, and the value of investments can fluctuate, potentially resulting in
financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE
PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT
INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A
SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
